可切除胰腺腺癌:CT定量影像生物标志物在预测病理特征与患者预后中的作用
该回顾性研究对两家大学医院的99例可切除胰腺导管腺癌患者术前门静脉期CT行纹理分析,评估定量影像生物标志物与病理侵袭性及无病生存的关系。结果显示肿瘤低衰减参数与分化分级、淋巴结侵犯相关,中央区衰减值<62 HU者1年无病生存率更低(35% vs 68%,p=0.004)。
要点
- 中央区衰减值(CENTRAL-AV)<62 HU者1年无病生存率35%,≥62 HU者为68%(p=0.004)。
- 全肿瘤平均衰减值(WHOLE-AV)与淋巴结侵犯相关(OR 0.886,95%CI 0.823-0.955)。
- 中央区衰减值(CENTRAL-AV)与肿瘤分化分级相关(OR 0.968,95%CI 0.94-0.998)。
核心结论
- 门静脉期CT上衰减更低的肿瘤可能更具侵袭性,表现为更高的肿瘤分级、更多的淋巴结侵犯和更短的无病生存期。
研究设计与样本
- 回顾性研究,纳入两家大学医院99例接受胰腺导管腺癌切除术的患者,对术前CT门静脉期行衰减测量与纹理分析。
关键影像表现/征象
- 肿瘤衰减参数包括全肿瘤平均衰减值(WHOLE-AV)和瘤内最低于衰减区(CENTRAL-AV)。
- 肿瘤异质性参数包括标准差、熵、偏度和峰度。
诊断标准与关键数值
- 肿瘤衰减参数与分化分级相关(CENTRAL-AV,OR 0.968,95%CI 0.94-0.998)。
- 肿瘤衰减参数与淋巴结侵犯相关(WHOLE-AV,OR 0.886,95%CI 0.823-0.955)。
- 与早期复发相关的变量:淋巴结比率(R2=0.15)、峰度(R2=0.08)、CENTRAL-AV(R2=0.04)。
- 淋巴结比率(HR 1.02)和CENTRAL-AV(HR 0.98)与更短的无病生存期独立相关。
- CENTRAL-AV<62 HU者1年无病生存率为35%,CENTRAL-AV≥62 HU者为68%(p=0.004)。
临床应用与阅片要点
- 术前门静脉期CT上测量肿瘤中央最低于衰减区(CENTRAL-AV)有助于提示肿瘤侵袭性和无病生存期。
- 全肿瘤平均衰减值(WHOLE-AV)降低可能提示淋巴结侵犯风险。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUNDS: Patients with a pancreatic cancer amenable to surgery still have a poor prognosis and high risk of post-operative recurrence. We aimed to assess the value of quantitative imaging biomarkers using computed-tomography (CT) texture analysis to evaluate the pathologic tumor aggressiveness and predict disease-free survival (DFS) in patients with resectable pancreatic adenocarcinoma.
METHODS: We retrospectively performed attenuation measurements and texture analysis on the portal-venous phase of the pre-operative CT scan of 99 patients that underwent resection of a pancreatic ductal adenocarcinoma in two university hospitals. Tumor attenuation parameters included: mean attenuation value of the whole tumor (WHOLE-AV), and of the most hypoattenuating area within the tumor (CENTRAL-AV). Tumor heterogeneity parameters included: standard deviation, entropy, skewness, and kurtosis.
RESULTS: Tumor attenuation parameters showed significant association with the tumor differentiation grade (CENTRAL-AV, Odds ratio (OR) 0.968, 95% confidence interval (CI) 0.94-0.998) and lymph node invasion (WHOLE-AV, OR 0.886, CI 0.823-0.955). Variables associated with early-recurrence were: lymph node ratio (R2=0.15), kurtosis (R2=0.08), and CENTRAL-AV (R2=0.04). Lymph node ratio (Hazard ratio (HR) 1.02), and CENTRAL-AV (HR 0.98) were independently associated with shorter DFS. Patients with CENTRAL-AV<62 Hounsfield units had a shorter 1-year DFS (35% versus 68%, p=0.004).
CONCLUSION: Tumors that are more hypoattenuating on the portal-venous phase on CT scan are potentially more aggressive with higher tumor grade, greater lymph node invasion, and shorter DFS.
引用
- Cassinotto C, Chong J, Zogopoulos G, et al. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes. Eur J Radiol. 2017. PMID: 28583627. doi:10.1016/j.ejrad.2017.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。